Drug manufacturers Merck and Moderna announced interim results from a phase three clinical trial testing a new personalized vaccine for high-risk melanoma. The vaccine, called Intismeran, was administered to patients following surgery alongside Keytruda, an existing immunotherapy medication. The companies reported that the combination treatment significantly extended the period during which patients remained free of cancer compared to Keytruda alone, and also reduced the likelihood of disease spreading to other organs.
The trial enrolled more than 1,000 patients with high-risk stage two, three, or four melanoma, encompassing cases ranging from large localized tumors to cancers that had already metastasized. The vaccine uses mRNA technology to target specific mutations in individual patients’ tumors. Scientists created the personalized jabs by surgically collecting a portion of each patient’s tumor, sequencing its DNA, and generating a vaccine designed to train the immune system to recognize and attack remaining malignant cells.
Cancer experts characterized the announcement as encouraging but cautioned that the findings remain preliminary. The full trial results have not yet undergone peer review by independent researchers, and the treatment would require regulatory approval and additional authorization before becoming available through the NHS. A prominent NHS cancer official described the approach as a significant advancement, noting it represents a shift toward directing the immune system to target cancer specifically rather than simply activating it broadly.
Both Moderna and Merck are developing similar personalized vaccine candidates for lung, bladder, and kidney cancers. Cancer research organizations acknowledged the promising preliminary data while emphasizing the need for continued funding and thorough review. More comprehensive findings from the study are scheduled for presentation at a medical conference in October.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI